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Nanoliposomes are new technological developments for the encapsulation and delivery of bioactive 
agents. Because of their biocompatibility and biodegradability, along with their size, nanoliposomes 
have potential applications in a vast range of fields, including nanotherapy. Nanoliposomes are able to 
enhance the performance of bioactive agents by improving their bioavailability, in vitro and in vivo 
stability, as well as preventing their unwanted interactions with other molecules [1].  
Nanoliposomes may contain, in addition to phospholipids, other molecules such as cholesterol (Ch) 
which is an important component of most natural membranes. The incorporation of Ch can increase 
stability by modulating the fluidity of the lipid bilayer preventing crystallization of the phospholipid acyl 
chains and providing steric hindrance to their movement. 
Further advances in liposome research found that polyethylene glycol (PEG), which is inert in the body, 
allows longer circulatory life of the drug delivery system [2].  
 
In this work, a potential antitumoral fluorescent indole derivative 1, methyl 6-methoxy-3-(4-
methoxyphenyl)-1H-indole-2-carboxylate (Figure 1), previously synthesized by us [3], has been 
encapsulated in different nanoliposome formulations, composed of egg-yolk phosphatidylcholine (Egg-
PC), dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidylglycerol (DPPG), distearoyl 
phosphatidylcholine (DSPC), with or without Ch and distearoyl phosphatidylethanolamine-(polyethylene 
glycol)2000 (DSPE-PEG).  
 
 
         
Figure 1. Structure of methyl 6-methoxy-3-(4-methoxyphenyl)-1H-indole-2-carboxylate. 
 
 
Compound 1 was evaluated for the in vitro cell growth inhibition on three human tumor cell lines, breast 
adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and a melanoma cell line (A375-C5), 
after a continuous exposure of 48 h, exhibiting low GI50 values in the three tumor cell lines (Table 1). 
 
 
Table 1. Values of compound 1 concentration needed for 50% of cell growth inhibition (GI50). 
 
GI50 (M) 
MCF-7 NCI-H460 A375-C5 
1 0.37  0.02 0.33  0.03 0.25  0.02 
 
 
Different formulations of nanoliposomes were prepared by injection of an ethanolic solution of the lipid 
mixture and compound 1 in an aqueous media under vigorous stirring, above the melting transition 
temperature of the lipids. The nanoliposomes prepared were then extruded (3 cycles) through a 100 nm 
polycarbonate filter. Hydrodynamic diameter, size distribution and zeta potential were measured by 
dynamic light scattering (DLS). These parameters were monitored in different days in order to determine 
the more stable formulations (Table 2). The results showed that nanoliposomes have sizes ≤ 120 nm 
and are generally monodisperse and stable after two weeks. Evaluation of the zeta potential of a 
nanoliposome preparation can help to predict the stability and in vivo fate of liposomes.  
 
 
 
Table 2. Hydrodynamic diameter, polidispersity and zeta potential of several nanoliposomes. 
 Mean Diameter (nm) Polidispersity Zeta potential (mV) 
Egg PC/Ch/DPPG 103.5 ± 0.9 0.124 ± 0.009 -51.9 ± 5.84 
2 weeks after 95.4 ± 0.53 0.138 ± 0.010  
DPPC/Ch/DSPE-PEG 115.4 ± 0.51 0.146 ± 0.008 -29.5 ± 1.16 
1 week after 116.3 ± 1.62 0.154 ± 0.008  
2 weeks after 116.0 ± 0.77 0.152 ± 0.011  
DSPC/Ch/DSPE-PEG 119.8 ± 2.00 0.190 ± 0.012 -26.9 ± 3.66 
  
Permeability studies of compound 1 between DPPC/DPPG liposomes (donor liposomes) and 
nitrobenzoxadiazole(NBD)-labelled DPPC/DPPG liposomes (acceptor liposomes) were performed using 
two different sizes of dialysis membranes (6-8 KDa and 12-14 KDa). For these experiments, three 
different fluorescent labelled lipids, bearing a NBD moiety in different positions of the phospholipids, 
NBD-PE (labelled at headgroup), NBD-C6-HPC and NBD-C12-HPC (labelled at fatty acid) were used 
(Figure 2 and 3). The transfer of compound 1 from DPPC/DPPG liposomes was monitored by FRET 
(Förster Resonance Energy Transfer) from compound 1 (energy donor) to the NBD-labelled lipids 
(energy acceptor). 
 
Figure 2. Chemical structure of the fluorescent-labelled lipids incorporated in nanoliposomes. 
 
 Figure 3. Schematic dialysis experiment and percentage of drug transfer through a dialysis membrane. 
 
Comparing the energy transfer to the several NBD-labelled lipids (Figure 3, right side), it can be 
concluded that compound 1 locates mainly near the polar head groups of phospholipids in the acceptor 
liposomes. It is also observed that compound 1 transfer is more efficient for the smaller dialysis 
membranes (6-8 KDa). 
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